Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 55,704 shares, a growth of 163.7% from the February 12th total of 21,126 shares. Based on an average daily trading volume, of 224,823 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.3% of the shares of the stock are short sold. Approximately 2.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 224,823 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on VRAX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $1.00 price objective (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. Finally, Zacks Research upgraded shares of Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $1.00.

Virax Biolabs Group Price Performance

NASDAQ VRAX opened at $0.20 on Wednesday. The stock’s fifty day moving average is $0.27 and its two-hundred day moving average is $0.44. Virax Biolabs Group has a fifty-two week low of $0.19 and a fifty-two week high of $1.58.

Virax Biolabs Group (NASDAQ:VRAX) last issued its earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share (EPS) for the quarter. The business had revenue of $0.00 million during the quarter.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.